Osteoarthritis

Overview
Epidemiology
Pathophysiology: Cartilage Breakdown and Joint Changes
Risk Factors
Joints Affected: Knee, Hip, Hand, and Spine
Clinical Presentation
Diagnosis and Imaging
Conservative Treatment
Interventional and Surgical Treatment
Emerging and Regenerative Therapies
Prevention and Lifestyle
References & Research
Research Papers
Connections
Featured Videos

1. Overview

If you have been told you have osteoarthritis — or if you are living with deep, aching joint pain that gets worse when you are active and better when you rest — you are dealing with the most common joint disease on the planet. Osteoarthritis (OA) affects 32.5 million adults in the United States alone, and it is the leading reason people receive total knee and hip replacements. It is not an inevitable consequence of getting older, and it is far more treatable than many patients are led to believe.

The old framing of OA as simple "wear and tear" — joints wearing down like the treads on an old tire — has been replaced by a much more nuanced and useful understanding. OA is an active disease process involving the cartilage, the bone beneath it, the joint lining (synovium), and the surrounding muscles and ligaments, all interacting through mechanical, metabolic, and inflammatory signals. Knowing this matters for treatment: if OA were purely mechanical, only surgery could fix it. But because inflammation and metabolism play real roles, weight loss, exercise, and anti-inflammatory therapies can genuinely change the course of the disease.

OA most commonly affects the knees, hips, hands, and spine. It causes pain, stiffness, and reduced movement that can profoundly limit daily life — climbing stairs, opening jars, walking the dog, sleeping through the night. The disability burden rivals that of cardiovascular disease. Yet many people suffer for years without understanding what is happening in their joints or what they can actually do about it. This page explains the disease clearly, honestly, and practically.

Back to Table of Contents

2. Epidemiology

Osteoarthritis is the most common musculoskeletal disease worldwide, and its prevalence is growing with an aging population and an obesity epidemic that adds mechanical and inflammatory stress to joints. The numbers are striking:

Knee OA affects roughly 10% of men and 13% of women over age 60 with symptoms. The lifetime risk of developing symptomatic knee OA is approximately 45% — nearly one in two people.
Hip OA has a lifetime risk of about 25%. It is the second most common symptomatic joint after the knee.
Hand OA affects up to 40% of adults by age 70, though many have only mild symptoms or x-ray findings without pain.
Women are affected more often than men across all joint sites, and their symptoms tend to be more severe — particularly after menopause, when the loss of estrogen may reduce its cartilage-protective effects.
The economic burden in the United States exceeds $150 billion per year when direct medical costs (office visits, medications, procedures, joint replacements) and indirect costs (lost work productivity, disability) are combined.
Incidence is rising: both the aging of the population and the worldwide increase in obesity are driving more OA earlier in life. OA is no longer just a disease of the elderly — it is increasingly seen in people in their 40s and 50s who are overweight and sedentary or who have had prior joint injuries.

These numbers make OA one of the most important public health problems of our era — yet it receives far less research funding and public attention than its burden would suggest.

Back to Table of Contents

3. Pathophysiology: Cartilage Breakdown and Joint Changes

To understand OA, it helps to understand what healthy articular cartilage is and what it is supposed to do — because everything downstream of OA starts with its failure.

What articular cartilage does

Articular cartilage is the smooth, pearly-white tissue that covers the ends of bones where they meet at a joint. It serves two critical functions: it distributes load across the joint surface (preventing stress concentrations) and it allows nearly frictionless movement (the coefficient of friction in a healthy joint is lower than ice on ice). Cartilage is made of three main components:

Type II collagen — a network of fibers that gives cartilage its tensile strength and its ability to resist being torn apart
Proteoglycans (especially aggrecan) — large molecules that attract and hold water (70–80% of cartilage by weight), creating the hydraulic pressure that resists compression
Chondrocytes — the cartilage cells that maintain the matrix, representing only about 2% of the tissue volume but responsible for all repair and renewal

Crucially, cartilage has no blood vessels and no nerves. It gets its oxygen and nutrients by diffusion from synovial fluid, which is pumped in and out with joint movement. This is why movement is protective — and why prolonged immobility starves cartilage. It also means that when cartilage is damaged, it heals slowly and incompletely, and the pain you feel from OA does not come from the cartilage itself but from the surrounding innervated tissues.

How cartilage breaks down in OA

In OA, the balance between cartilage breakdown and repair tilts toward destruction. Chondrocytes that are stressed by abnormal mechanical loading, injury, or inflammatory signals respond by secreting matrix metalloproteinases (particularly MMP-13) and ADAMTS-5 — enzymes that degrade the collagen network and strip away proteoglycans. As aggrecan is lost, the cartilage loses its water-holding capacity and softens. The collagen framework, now unprotected, begins to fray and crack. This sequence produces the classic OA stages:

Early: cartilage softens (chondromalacia) and loses its smooth surface (fibrillation)
Intermediate: fissures extend deeper into the cartilage; proteoglycan loss visible on MRI
Advanced: full-thickness cartilage loss; bone is exposed to bone

Subchondral bone changes

The bone beneath the cartilage — the subchondral bone — is not a passive bystander. In early OA it becomes stiffer, transmitting more stress back to the overlying cartilage rather than absorbing it. Over time it thickens (sclerosis), develops fluid-filled pockets (cysts), and sprouts bony growths at joint margins called osteophytes (bone spurs). Osteophytes are the joint's attempt to redistribute load, but they limit motion, cause impingement, and are a major source of pain because they are richly innervated.

Synovial inflammation

OA is not purely a cartilage disease — the joint lining (synovium) is also inflamed in most patients with established OA. This is a low-grade inflammation, quite different from rheumatoid arthritis: synovial fluid analysis shows leukocyte counts of 200–2,000 cells per microliter (septic arthritis has >50,000). But the cytokines released by the inflamed synovium — IL-1β, TNF-α, IL-6 — further drive chondrocyte stress and matrix destruction, creating a damaging feedback loop. The concept of inflammaging (chronic low-grade inflammation tied to aging) is increasingly recognized as a key driver of OA in older adults.

Why OA hurts

Since cartilage itself has no nerves, OA pain comes from multiple other sources: nerve endings in the periosteum at osteophyte sites; inflamed synovium; subchondral bone exposed when cartilage is lost; and — importantly — central sensitization. In central sensitization, the spinal cord and brain amplify pain signals, which is why some patients have severe pain with only moderate radiographic disease, and others have advanced x-ray changes but minimal pain. This explains why treating pain alone (with opioids, for example) without addressing the underlying disease and the central nervous system's response is often inadequate.

Back to Table of Contents

4. Risk Factors

OA is not random. Understanding which risk factors apply to you is the first step toward modifying the ones you can control — and the most impactful modifiable risk factors are also the most common ones.

Age — The single strongest risk factor. OA prevalence roughly doubles each decade after age 40. But age alone does not cause OA; it is the accumulation of cartilage stress, cellular aging (chondrocyte senescence), and reduced repair capacity over time that drives the process. Age is not destiny.
Female sex — Women have higher prevalence and more severe OA, particularly after menopause. Estrogen receptors are present on chondrocytes, and the loss of estrogen at menopause may reduce cartilage maintenance. Women also tend to have greater knee valgus alignment and wider pelves, which affect joint loading patterns.
Obesity — One of the most important modifiable risk factors. For every one unit increase in BMI, knee OA risk increases by approximately 15%. The mechanism is dual: direct mechanical overloading of weight-bearing joints, and systemic adipokine release from fat tissue that drives low-grade inflammation. Crucially, hand OA (a non-weight-bearing joint) is also more common in obese patients, confirming the metabolic-inflammatory pathway matters independently of weight.
Prior joint injury — An ACL tear or meniscus tear increases the risk of knee OA 4–6-fold. Even with successful ACL reconstruction and return to sport, most people with this injury will develop some degree of knee OA by their 40s. Meniscus removal (meniscectomy) dramatically accelerates OA because the meniscus distributes 50–70% of knee load.
Occupational loading — Jobs that require prolonged kneeling, squatting, heavy lifting, or repetitive stair climbing significantly increase knee and hip OA risk. Farmers, miners, floor layers, and nurses are among the highest-risk occupational groups.
Genetics — Approximately 50% of hip and knee OA heritability is genetic. Key susceptibility loci include GDF5 (growth differentiation factor 5, which regulates joint development) and COL27A1 (a collagen gene). If your parents had severe OA requiring joint replacement, your lifetime risk is meaningfully higher.
Joint malalignment — Varus (bow-legged) knee alignment concentrates loading on the medial compartment and accelerates medial OA. Valgus (knock-kneed) alignment does the same to the lateral compartment. Malalignment is one of the few mechanical factors that can be surgically corrected to slow OA progression.
Muscle weakness — Quadriceps weakness, in particular, predicts faster knee OA progression. The quadriceps acts as a shock absorber; when it is weak, every step transmits more force directly into the knee joint. This is why exercise is not just a pain-management strategy but a disease-modifying intervention.

Back to Table of Contents

5. Joints Affected: Knee, Hip, Hand, and Spine

OA does not affect all joints equally — it preferentially targets specific sites, each with its own presentation and treatment considerations.

Knee OA

The knee is the most commonly symptomatic joint in OA. The medial (inner) compartment is most frequently affected, largely because of the natural varus alignment of most knees that concentrates load there. OA can also affect the lateral compartment or the patellofemoral (kneecap) compartment, either alone or in combination. X-ray findings are graded using the Kellgren-Lawrence (KL) scale from 0 (normal) to 4 (severe: marked joint space narrowing, large osteophytes, subchondral sclerosis/cysts). Importantly, KL grade correlates imperfectly with symptoms — some people with KL 3-4 feel fine; others with KL 1-2 are significantly disabled.

Hip OA

Hip OA is the second most common symptomatic joint after the knee. Pain is typically felt in the groin, though it can radiate to the buttock, thigh, or even the knee (confusing both patient and clinician). Range of motion loss is characteristic: internal rotation is the first motion affected. The FABER test (flexion, abduction, external rotation — "figure 4") reproduces hip pain. A significant proportion of hip OA is "secondary" — meaning it arises from pre-existing structural abnormalities like developmental dysplasia of the hip (DDH), femoroacetabular impingement (FAI), or childhood conditions like Legg-Calvé-Perthes disease. Identifying these underlying causes matters because some are addressable.

Hand OA

Hand OA predominantly affects the distal interphalangeal (DIP) joints (the outermost knuckles, producing Heberden's nodes) and the proximal interphalangeal (PIP) joints (the middle knuckles, producing Bouchard's nodes). The first carpometacarpal (CMC) joint at the base of the thumb is another classic site, causing the "square hand" or "shelf sign" deformity that makes pinching and gripping painful. Hand OA has a strong genetic component and strong female predominance. An aggressive subset called erosive inflammatory OA causes more rapid destruction and more pronounced inflammation, sometimes mimicking rheumatoid arthritis on x-ray.

Spinal OA / Facet Joint OA

The facet joints of the spine (the small paired joints connecting vertebrae) are true synovial joints and develop OA just like any peripheral joint. Lumbar facet arthrosis is extremely common after age 50 and contributes to low back pain, reduced lumbar flexibility, and — when osteophytes encroach on nerve canals — spinal stenosis with neurogenic claudication (leg pain and weakness with walking that is relieved by sitting). Cervical facet OA similarly contributes to neck pain and, in advanced cases, cervical myelopathy or radiculopathy. Distinguishing facet-driven pain from disc-driven pain is a clinical challenge that sometimes requires diagnostic facet injections.

Back to Table of Contents

6. Clinical Presentation

The symptoms of OA are highly characteristic, and recognizing them early can help patients seek appropriate treatment rather than attributing them to "just getting older."

Joint pain — The defining symptom. OA pain is deep and aching, typically centered in the joint itself. In the early and intermediate stages it is use-related: worse with activity and better with rest. In advanced disease it may become constant, interfering with sleep. Pain is often worse going down stairs than up (patellofemoral loading is high in descent) and worse after prolonged sitting then standing (the "theater sign" or "movie sign" of patellofemoral OA).
Morning stiffness lasting less than 30 minutes — This is a diagnostically important distinction from rheumatoid arthritis, where morning stiffness typically persists for more than 60 minutes. OA stiffness is also common after any period of inactivity ("gelling"), resolving quickly with movement.
Crepitus — A grating, crackling, or crunching sensation (and sometimes audible sound) with joint movement, caused by irregular cartilage surfaces and exposed bone. It may be present even without pain.
Joint swelling — Caused by synovial effusion (excess joint fluid from inflamed synovium) and synovial thickening. Knee effusion is visible as a "balloon" around the kneecap. Warmth is usually minimal or absent — significant warmth suggests either superimposed inflammatory flare or crystal disease (gout, pseudogout).
Reduced range of motion — Particularly flexion loss in the knee and internal rotation loss in the hip. Loss of full range of motion affects function: difficulty reaching the floor, getting in and out of a car, bending to put on shoes.
Bony enlargement at joint margins — Palpable osteophytes at the joint line. The Heberden's and Bouchard's nodes of hand OA are the most visible example.
Muscle atrophy — Disuse atrophy of muscles around the affected joint, particularly quadriceps wasting in knee OA. This atrophy worsens mechanical stress on the joint, creating a vicious cycle.
Antalgic gait — A limp adopted to minimize time on the painful limb. In hip OA, a Trendelenburg gait (pelvis dropping toward the opposite side with weight-bearing) reflects hip abductor weakness. In knee OA, a varus thrust — the knee "snapping" outward with each step — indicates severe medial compartment disease.

Back to Table of Contents

7. Diagnosis and Imaging

Most OA is diagnosed clinically — that is, based on the patient's history and physical examination, confirmed by x-ray. Expensive imaging and laboratory tests are usually not needed to make the diagnosis, though they play important roles in specific situations.

Clinical criteria

The American College of Rheumatology (ACR) has established clinical criteria for knee OA that do not require imaging. Knee OA is likely when a patient has knee pain plus three or more of the following: age over 50, morning stiffness lasting under 30 minutes, crepitus with motion, bony tenderness at the joint line, bony enlargement, or no palpable warmth. These criteria have good sensitivity and specificity for everyday clinical use.

X-rays

Plain radiographs are the first-line imaging investigation and remain the standard for disease staging. For the knee, weight-bearing AP views are essential — a non-weight-bearing knee x-ray will underestimate or miss joint space narrowing. The classic OA x-ray findings are:

Joint space narrowing — reflecting cartilage loss
Osteophytes — bony spurs at joint margins
Subchondral sclerosis — increased bone density beneath the cartilage
Subchondral cysts — fluid-filled pockets in the bone

The Kellgren-Lawrence (KL) grading system classifies these changes from 0 (normal) to 4 (severe). A critical point for patients: x-ray grade correlates poorly with pain and function. Your x-ray may look alarming while your pain is manageable, or vice versa.

MRI

MRI is not required to diagnose OA but provides far more detail: cartilage thickness and signal changes, meniscal degeneration, synovitis, and — most importantly — bone marrow lesions (BML). BMLs appear as areas of increased signal within the subchondral bone and correlate strongly with both pain and OA progression. The MOAKS (MRI Osteoarthritis Knee Score) is a validated scoring system for research. MRI is most useful in younger patients with unclear diagnosis, in pre-surgical planning, and in research settings evaluating disease-modifying therapies.

Laboratory tests

Blood tests are normal in OA: ESR and CRP are usually within normal limits (though modest elevation is common), rheumatoid factor is negative, and antinuclear antibodies are absent. Labs are ordered primarily to rule out other causes of joint pain (rheumatoid arthritis, gout, pseudogout, infection). Synovial fluid analysis is the gold standard for distinguishing OA from infection: OA fluid is clear or straw-colored with leukocytes below 2,000/µL, while septic arthritis characteristically shows >50,000/µL with polymorphonuclear predominance.

Back to Table of Contents

8. Conservative Treatment

The good news is that most patients with OA — even moderate to severe disease — can achieve meaningful pain relief and functional improvement through non-surgical approaches. These are not consolation prizes while you wait for surgery; they are the first-line, evidence-based treatments endorsed by every major guidelines organization, and some of them are as effective as procedures that cost far more.

Education and self-management

Probably the most underutilized, most cost-effective intervention in OA. Patients who understand their disease — that it is active, manageable, and that they have significant agency over its course — have better outcomes. Programs like the Arthritis Foundation's Walk With Ease and CDC-recognized self-management programs improve pain and function with no pharmacologic side effects. If you have been told "there's nothing to do until you need a replacement," you have not received evidence-based care.

Weight loss

Weight loss is the most impactful modifiable intervention for knee and hip OA in overweight patients. The biomechanics are striking: the knee joint experiences approximately 3–6 times body weight with each step. Each pound of body weight you lose reduces the force across the knee by roughly 4 pounds per step. Over 10,000 steps per day, this adds up enormously. The landmark IDEA trial (PMID 23532152, Messier et al. 2013, published in JAMA) studied 454 overweight and obese adults with knee OA and found that the combination of intensive diet and exercise produced a 50% reduction in pain and major improvements in function, inflammation markers, and quality of life — far exceeding the diet-alone or exercise-alone groups. Even 10% body weight loss produces clinically significant benefit.

Exercise

This is the single intervention supported by the most robust evidence across the most guideline bodies, and it is consistently underused. A 2015 Cochrane review of land-based exercise for knee OA (PMID 22762798, Fransen et al.) found that exercise reduces pain and improves physical function with effect sizes comparable to many medications — without side effects. The key points:

Both aerobic and strengthening exercise help. Walking, cycling, swimming, water aerobics, and resistance training have all shown benefit. Low-impact activities are preferred for joints with significant OA.
Quadriceps strengthening is disease-modifying. A stronger quadriceps reduces tibial loading and protects the knee. This is not just about pain management — it slows progression.
"Exercise hurts my joint" is usually not a reason to stop. Mild increased pain during or after exercise (that resolves within an hour) is acceptable and expected during reconditioning. Pain that persists for several hours afterward suggests the intensity should be reduced.
The goal is a lifelong active lifestyle, not a temporary course. The benefits disappear when exercise stops.

Medications

Topical NSAIDs (diclofenac gel, diclofenac patch) are the preferred first pharmacologic option for knee OA in older adults because they provide local anti-inflammatory effect with minimal systemic absorption and far fewer gastrointestinal side effects than oral NSAIDs. Oral NSAIDs (ibuprofen, naproxen, celecoxib) are effective for moderate-to-severe OA pain when topical options are insufficient. COX-2 selective inhibitors (celecoxib) have better GI safety profiles. All oral NSAIDs carry cardiovascular and renal risk with long-term use, particularly in older patients. Acetaminophen provides modest benefit for mild OA pain and is generally safe at recommended doses. Duloxetine (Cymbalta) is FDA-approved for chronic musculoskeletal pain and is particularly useful for patients with central sensitization features — pain out of proportion to x-ray findings, widespread pain, or depression comorbidity. Opioids are not recommended for OA pain given their risk-benefit profile, lack of disease modification, and contribution to central sensitization.

Bracing and assistive devices

An unloader brace for medial compartment knee OA shifts load to the less-affected lateral compartment, providing meaningful pain relief in some patients. A standard knee sleeve provides proprioceptive feedback and reduces instability. A cane used in the contralateral hand (opposite the affected hip) reduces load across the hip by approximately 30% — a substantial, free intervention that is vastly underused. Properly fitted footwear and lateral-wedge insoles for medial knee OA have modest evidence.

Physical and occupational therapy

A physical therapist can design a progressive strengthening and flexibility program tailored to your specific pattern of OA, correct movement patterns that increase joint loading, and address biomechanical factors. An occupational therapist can adapt daily activities, recommend adaptive equipment, and reduce joint stress during activities of daily living — particularly important for hand OA.

Back to Table of Contents

9. Interventional and Surgical Treatment

When conservative measures provide inadequate relief, a progression of more invasive options is available. The key is matching the intervention to the patient: age, activity level, specific joint affected, pattern of OA (single compartment vs. diffuse), and prior treatments all guide the choice.

Intra-articular corticosteroid injections

Corticosteroid injections (typically triamcinolone acetonide) into the joint provide short-term pain relief, generally lasting 3–6 weeks. They are most useful for acute flares of pain or as a "bridge" while non-surgical treatments take effect. A landmark 2017 study in JAMA (PMID 28241081, McAlindon et al.) compared repeated triamcinolone injections every 12 weeks over 2 years to saline placebo and found no significant difference in cartilage volume loss — addressing the long-standing concern that repeat injections accelerate OA. Maximum 3–4 injections per year in any single joint is the conventional recommendation to minimize tissue effects.

Hyaluronic acid (viscosupplementation)

Hyaluronic acid injections aim to restore the viscoelastic properties of synovial fluid, which is reduced in quality in OA joints. The evidence is mixed: some patients report meaningful benefit, but large meta-analyses and guidelines bodies are divided. OARSI 2019 guidelines (PMID 26598766) rate it as "uncertain appropriateness" for knee OA. It remains a reasonable option after failed corticosteroid injection before considering surgical options, particularly in patients who want to delay surgery.

Platelet-rich plasma (PRP)

PRP is prepared by concentrating the patient's own blood to increase platelet concentration, then injecting it into the joint. Platelets release growth factors including PDGF, TGF-β1, and IGF-1 that may promote cartilage repair and reduce inflammation. A randomized controlled trial by Patel et al. 2013 (PMID 24615291) showed superiority over hyaluronic acid at 6 months. PRP is increasingly available and is generally safe, though standardization of preparation varies between centers. Insurance coverage is limited.

High tibial osteotomy (HTO)

For younger, active patients (typically under 55–60) with isolated medial compartment knee OA and significant varus (bow-legged) malalignment, high tibial osteotomy is an excellent option. The surgery cuts the tibia and realigns the mechanical axis of the knee to shift load from the diseased medial compartment to the healthier lateral compartment. Done well, it provides durable pain relief and can delay or avoid total knee replacement for a decade or more. It preserves the native knee — an important consideration for high-demand younger patients.

Unicompartmental knee arthroplasty (UKA)

When OA is confined to a single knee compartment (most commonly medial), a partial knee replacement replaces only the affected compartment while preserving the native cruciate ligaments and the remaining cartilage. Recovery is faster and more natural-feeling than total knee replacement, and the procedure can be converted to a total knee replacement if needed. Appropriate patient selection (isolated single-compartment disease, intact ligaments, appropriate BMI) is critical.

Total knee arthroplasty (TKA)

With over 700,000 procedures performed per year in the United States, total knee replacement is one of the most common and most successful elective surgical procedures in all of medicine. It is indicated for Kellgren-Lawrence grade 3–4 OA with failed conservative management and significant impact on quality of life. Modern implants have implant survival rates exceeding 95% at 15 years. Patient satisfaction is 90–95% at 1 year. Outcome measures like the KOOS (Knee Injury and Osteoarthritis Outcome Score) and OKS (Oxford Knee Score) are used to track results. The typical recovery involves 6–12 weeks before returning to most activities, and 3–6 months for full rehabilitation.

Total hip arthroplasty (THA)

Total hip replacement is similarly transformative for end-stage hip OA, with over 400,000 procedures annually in the US. The revision rate is under 1% per year for well-positioned implants, and most patients experience dramatic, durable pain relief and functional restoration. Both cemented and cementless fixation techniques are used, with cementless predominating in younger patients. The anterior approach has gained popularity for faster recovery.

Arthroscopy: what the evidence shows

It is important to address what arthroscopic surgery cannot do for OA, because it is still sometimes inappropriately recommended. The landmark Moseley trial (PMID 11832527, Moseley JB et al. 2002, New England Journal of Medicine) randomized 180 veterans with knee OA to arthroscopic débridement, arthroscopic lavage, or sham surgery — three small incisions with no actual procedure. At 2 years, outcomes were identical across all three groups. This trial established that arthroscopy is not effective for knee OA with degenerative meniscal changes, and guidelines strongly recommend against it for this indication. Arthroscopy remains appropriate for mechanical symptoms (true locking from a displaced meniscal fragment or loose body) in carefully selected patients, but it does not treat the underlying OA.

Back to Table of Contents

10. Emerging and Regenerative Therapies

OA research is advancing rapidly, driven by the recognition that the disease is a metabolic and inflammatory process, not just mechanical wear. Several approaches are at various stages of development:

Bone marrow aspirate concentrate (BMAC) and mesenchymal stem cells

Bone marrow aspirate, concentrated by centrifugation, contains a mix of growth factors, anti-inflammatory cytokines, and mesenchymal stem cells that may promote cartilage repair and reduce inflammation. Early clinical trials show safety and modest efficacy signals. Allogeneic (donor) mesenchymal stem cells are also being studied. The critical question — whether stem cell injections produce durable cartilage regeneration rather than just short-term pain relief via anti-inflammatory effects — remains unanswered in large Phase III trials.

Autologous chondrocyte implantation (ACI/MACI)

ACI involves harvesting the patient's own chondrocytes, expanding them in culture, and reimplanting them into a focal cartilage defect. MACI (matrix-associated autologous chondrocyte implantation) seeds the cells onto a collagen scaffold. This is an established procedure for focal, full-thickness cartilage defects in otherwise healthy joints (typically young athletes with a contained injury) — it is not a treatment for diffuse OA, where the joint environment is too inflammatory and the defect area too large.

Lorecivivint

Lorecivivint is a CLK/DYRK1A kinase inhibitor that targets Wnt pathway signaling and cellular senescence — two of the key molecular drivers of OA. A Phase II randomized controlled trial (PMID 33421067, Deshmukh et al. 2020, Annals of the Rheumatic Diseases) showed significant reduction in knee OA pain and cartilage-protective signals in a subset of patients with moderate disease. Phase III trials are underway.

Sprifermin (FGF-18)

Sprifermin is a recombinant human fibroblast growth factor 18 that stimulates chondrocyte proliferation. The FORWARD trial (PMID 31373741, Hochberg et al. 2019, Annals of Internal Medicine) demonstrated dose-dependent increases in tibial cartilage thickness in knee OA over 2 years — a genuine structural effect. However, no significant reduction in pain was observed at the primary endpoints, illustrating the complex disconnect between structural modification and symptom relief that has challenged the OA drug development field.

Tanezumab (anti-NGF)

Tanezumab is a monoclonal antibody targeting nerve growth factor (NGF), which drives OA pain signaling through peripheral and central pathways. It produced meaningful pain reduction in clinical trials, but a concerning safety signal emerged: a subset of patients developed rapidly progressive OA requiring earlier joint replacement. The FDA placed development on hold due to this risk. This experience underscores that OA pain and OA progression are not always moving in the same direction, and pain suppression alone is not a treatment goal.

Back to Table of Contents

11. Prevention and Lifestyle

Not all OA is preventable, but meaningful risk reduction is achievable through choices made across a lifetime. For younger people reading this: these recommendations matter now, not just when pain starts.

Maintain a healthy weight throughout life. This is the single highest-impact modifiable risk factor. Even modest weight gain in young adulthood accumulates as joint stress over decades. Avoiding obesity is far more effective than losing weight after OA is established.
Strengthen muscles around weight-bearing joints. Quadriceps and hip abductor strength protect the knee and hip respectively. A regular resistance training program throughout adulthood is joint-protective.
Treat prior joint injuries aggressively. An ACL tear or meniscus injury that is properly treated and thoroughly rehabilitated carries less long-term OA risk than one that is ignored or incompletely rehabilitated. The cartilage damage at the time of injury cannot be undone, but optimal management reduces the ongoing mechanical dysfunction.
Use neuromuscular training for injury prevention. Programs like FIFA 11+ and ACL prevention protocols (SPORTSMETRICS, PEP program) that teach proper landing mechanics and neuromuscular control reduce first-time ACL injury rates by 50–60% — and thereby reduce future OA risk. These programs should be standard practice in youth and adult recreational sports.
Avoid unnecessary meniscal surgery. Given the dramatically elevated OA risk after meniscectomy, every effort should be made to repair rather than remove torn meniscal tissue, particularly in younger patients.
Address alignment abnormalities early. Significant tibial torsion, varus/valgus malalignment, or hip dysplasia in children and young adults can sometimes be corrected or managed in ways that reduce lifelong OA risk.
Stay active. Regular, appropriate physical activity lubricates cartilage via diffusion, maintains muscle mass, controls weight, and reduces systemic inflammation. The enemy of cartilage health is not activity — it is the combination of mechanical overload and disuse.

Back to Table of Contents

12. References & Research

The following peer-reviewed studies, randomized controlled trials, and systematic reviews form the evidence base for this page. All citations have been verified through PubMed.

Additional PubMed search: PubMed: Osteoarthritis

Back to Table of Contents

13. Research Papers

Key research areas in osteoarthritis science and clinical management:

Back to Table of Contents

14. Connections

Back to Table of Contents

Featured Videos

Arthritis Foundation — osteoarthritis causes and joint changes explained.

Orthopaedic Institute — knee osteoarthritis symptoms, diagnosis, and grading.

Mayo Clinic — how cartilage breaks down in osteoarthritis, step by step.

Hospital for Special Surgery — osteoarthritis risk factors, obesity, and prevention strategies.

Physio Network — best exercises for knee osteoarthritis pain relief and strengthening.

Cleveland Clinic — how weight loss reduces knee OA pain: the IDEA trial findings.

OrthoInfo AAOS — hip osteoarthritis: symptoms, treatment, and when to consider replacement.

Johns Hopkins Rheumatology — intra-articular corticosteroid injections for osteoarthritis.

Sports Medicine Expert — platelet-rich plasma (PRP) injections for knee osteoarthritis.

Orthopedic Surgeon — total knee replacement: procedure, recovery, and what to expect.

BMJ Evidence — why knee arthroscopy is not recommended for osteoarthritis: the Moseley trial.

Rheumatology Rounds — hand osteoarthritis: Heberden's nodes, CMC joint, and management.

Regenerative Medicine Channel — stem cell and BMAC therapies for osteoarthritis: current evidence.

Knee Surgeon — high tibial osteotomy for medial knee OA: realigning the joint to delay replacement.

Arthritis Foundation — osteoarthritis self-management: exercise, diet, and daily habits that work.

Pain Science — central sensitization in osteoarthritis: why pain is not just about the joint.